Aldeyra Therapeutics (ALDX) EBITDA (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly EBITDA came in at -$3.5 million in Q1 2026, up 65.98% YoY from -$2.1 million in Q1 2025, and up 46.81% on a QoQ basis from -$6.7 million in Q4 2025.
Aldeyra Therapeutics (ALDX) EBITDA (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of EBITDA data on file, last reported at -$3.5 million in Q1 2026.
- Quarterly EBITDA rose 65.98% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.4 million (up 53.58% YoY) and the FY2025 annual result came in at -$35.3 million, up 41.34% from the prior year.
- EBITDA improved to -$3.5 million in Q1 2026, from -$6.7 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$3.5 million in Q1 2026 to a low of -$18.0 million in Q2 2024.
- A 5-year average of -$12.0 million and a median of -$10.4 million in 2025 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2024 — EBITDA sank 171.87% — and 2026, when it surged 65.98%.
- Tracing ALDX's EBITDA over 5 years: stood at -$13.7 million in 2022, then jumped by 55.48% to -$6.1 million in 2023, then sank by 171.87% to -$16.6 million in 2024, then surged by 59.78% to -$6.7 million in 2025, then surged by 46.81% to -$3.5 million in 2026.
- The last three EBITDA figures came in at -$3.5 million (Q1 2026), -$6.7 million (Q4 2025), and -$8.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Aldeyra Therapeutics | 91.08 Mn | 91.08 Mn | - | -5.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.85 Mn |
| Mar 31, 2026 | -3.55 Mn |
| Dec 31, 2025 | -6.67 Mn |
| Sep 30, 2025 | -8.00 Mn |
| Jun 30, 2025 | -10.17 Mn |
| Mar 31, 2025 | -10.43 Mn |
| Dec 31, 2024 | -16.58 Mn |
| Sep 30, 2024 | -16.14 Mn |
| Jun 30, 2024 | -18.01 Mn |
| Mar 31, 2024 | -9.39 Mn |
| Dec 31, 2023 | -6.10 Mn |
| Sep 30, 2023 | -9.55 Mn |
| Jun 30, 2023 | -10.34 Mn |
| Mar 31, 2023 | -16.80 Mn |
| Dec 31, 2022 | -13.70 Mn |
| Sep 30, 2022 | -14.78 Mn |
| Jun 30, 2022 | -17.71 Mn |
| Mar 31, 2022 | -16.48 Mn |
| Dec 31, 2021 | -15.40 Mn |
| Sep 30, 2021 | -15.44 Mn |